Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2017 | Pages:
52 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Pipeline Review, H1 2017 Summary According to the recently published report 'Islet Amyloid Polypeptide - Pipeline Review, H1 2017'; Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) pipeline Target constitutes close to 14 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Islet amyloid polypeptide (IAPP) or Amylin is a peptide hormone. This hormone is released from pancreatic beta cells following food intake to regulate blood glucose levels and act as a satiation signal. It inhibits insulin-stimulated glucose utilization and glycogen deposition in muscle. The report 'Islet Amyloid Polypeptide - Pipeline Review, H1 2017' outlays comprehensive information on the Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities. It also reviews key players involved in Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase I, Preclinical and Discovery stages are 2, 9 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Musculoskeletal Disorders, Gastrointestinal and Central Nervous System which include indications Type 2 Diabetes, Obesity, Osteoarthritis, Type 1 Diabetes (Juvenile Diabetes), Non-Alcoholic Steatohepatitis (NASH), Alzheimer's Disease and Non Alcoholic Fatty Liver Disease (NAFLD). Scope - The report provides a snapshot of the global therapeutic landscape for Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - The report reviews Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP)targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP)targeted therapeutics and enlists all their major and minor projects - The report assesses Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP)development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Overview Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Companies Involved in Therapeutics Development Adocia AstraZeneca Plc Neurimmune Holding AG Nordic Bioscience A/S reMYND NV Zealand Pharma AS Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Drug Profiles (insulin human + pramlintide acetate) - Drug Profile Product Description Mechanism Of Action R&D Progress (insulin lispro + pramlintide) - Drug Profile Product Description Mechanism Of Action R&D Progress AC-253 - Drug Profile Product Description Mechanism Of Action R&D Progress KBP-042 - Drug Profile Product Description Mechanism Of Action R&D Progress KBP-056 - Drug Profile Product Description Mechanism Of Action R&D Progress KBP-089 - Drug Profile Product Description Mechanism Of Action R&D Progress NI-203 - Drug Profile Product Description Mechanism Of Action R&D Progress ReS-13 - Drug Profile Product Description Mechanism Of Action R&D Progress ReS-39 - Drug Profile Product Description Mechanism Of Action R&D Progress salmon calcitonin - Drug Profile Product Description Mechanism Of Action R&D Progress Synthetic Peptides to Target IAPP for Obesity and Diabetes - Drug Profile Product Description Mechanism Of Action R&D Progress UGP-302 - Drug Profile Product Description Mechanism Of Action R&D Progress ZP-4982 - Drug Profile Product Description Mechanism Of Action R&D Progress ZP-5461 - Drug Profile Product Description Mechanism Of Action R&D Progress Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Dormant Products Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Discontinued Products Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Product Development Milestones Featured News & Press Releases May 11, 2017: Zealand Pharma discloses amylin as the biological target under their 2014 agreement with Boehringer Ingelheim Jan 05, 2017: Adocia Launches New Multi-Hormonal Combination Project For Treatment Of Type 1 Diabetes Jun 08, 2016: Zealand presents new data on proprietary preclinical peptide drug candidates at the 76th Annual American Diabetes Associations Scientific Sessions Aug 19, 2015: Nordic Bioscience Announces Successful Completion of Phase I study for KBP-042 May 05, 2014: reMYND's novel diabetes treatment prevents - and even reverses - disease progression in pre-clinical diabetes models Apr 10, 2013: Centennial Lecture features research on restoring memory and movement Dec 11, 2012: University Of Alberta Medical Researchers Make Key Discovery In Fight Against Alzheimer's Disease Aug 15, 2012: Unigene Labs And Nordic Bioscience Announce Preliminary Selection Of Lead Compound For Treatment Of Type 2 Diabetes Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H1 2017 Number of Products under Development by Therapy Areas, H1 2017 Number of Products under Development by Indication, H1 2017 Number of Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Investigation by Universities/Institutes, H1 2017 Products under Investigation by Universities/Institutes, H1 2017 Number of Products by Stage and Mechanism of Actions, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Pipeline by Adocia, H1 2017 Pipeline by AstraZeneca Plc, H1 2017 Pipeline by Neurimmune Holding AG, H1 2017 Pipeline by Nordic Bioscience A/S, H1 2017 Pipeline by reMYND NV, H1 2017 Pipeline by Zealand Pharma AS, H1 2017 Dormant Projects, H1 2017 Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
